TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of
patients with unresectable or metastatic melanoma with BRAF V600E
mutation as detected by an FDA-approved test.
TAFINLAR is indicated, in combination with trametinib, for:
• the treatment of patients with unresectable or metastatic melanoma with
BRAF V600E or V600K mutations as detected by an FDA-approved test.
• the adjuvant treatment of patients with melanoma with BRAF V600E or
V600K mutations, as detected by an FDA-approved test, and involvement
of lymph node(s), following complete resection.
• the treatment of patients with metastatic non-small cell lung cancer
(NSCLC) with BRAF V600E mutation as detected by an FDA-approved
test.
• the treatment of patients with locally advanced or metastatic anaplastic
thyroid cancer (ATC) with BRAF V600E mutation and with no
satisfactory locoregional treatment options.
• the treatment of adult and pediatric patients 6 years of age and older with
unresectable or metastatic solid tumors with BRAF V600E mutation who
have progressed following prior treatment and have no satisfactory
alternative treatment options.
